1,059 followers
Now showing SONAR data. Atrosentan associated with decreased risk of doubling of creatinine. Again with more adverse events. #kidneywk https://www.thelancet.com/article/S0140-6736(19)30772-X/fulltext
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Overview of attention for article published in The Lancet, April 2019
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (89th percentile)
Mentioned by
- news
- 14 news outlets
- blogs
- 2 blogs
- policy
- 1 policy source
- 174 X users
- patent
- 21 patents
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- f1000
- 1 research highlight platform
- guideline
- 1 clinical guideline source
- bluesky
- 1 Bluesky user
- podcasts
- 1 podcast
Readers on
- mendeley
- 436 Mendeley